Show simple item record

dc.contributor.authorMagnussen, Marita D
dc.contributor.authorGaini, Shahin
dc.contributor.authorGislason, Hannes
dc.contributor.authorKristinsson, Karl G
dc.date.accessioned2016-08-24T11:37:25Z
dc.date.available2016-08-24T11:37:25Z
dc.date.issued2016-04
dc.date.submitted2016
dc.identifier.citationAntibacterial resistance in Streptococcus pyogenes (GAS) from healthy carriers and tonsillitis patients and association with antibacterial sale in the Faroe Islands. 2016, 124 (4):327-32 APMISen
dc.identifier.issn1600-0463
dc.identifier.pmid26833774
dc.identifier.doi10.1111/apm.12513
dc.identifier.urihttp://hdl.handle.net/2336/618732
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractThe aim of this study was to investigate the antibacterial resistance of Streptococcus pyogenes (GAS), and correlate the findings with the sales of erythromycin and tetracycline. General practitioners in the Faroe Islands were recruited to send oropharyngeal swabs. From an ongoing pneumococcal study, nasopharyngeal swabs were sampled from healthy children 0-7 years of age. Erythromycin susceptibility data from Iceland were obtained from the reference laboratory at the Landspitali University Hospital. Susceptibility testing in the Faroe Islands and Iceland was performed according to CLSI methods and criteria. The resistance rate to erythromycin and tetracycline found in patients in the Faroe Islands in 2009/2010 was 6% and 30% respectively. Tetracycline resistance in patients declined significantly from 2009 to 2010 (37-10%, p-value = 0.006 < 0.05) and differed significantly between age groups (p-value = 0.03 < 0.05). In Iceland, there was a peak in erythromycin resistance in 2008 (44%) and a substantial decrease in 2009 (5%). Although the prevalence of erythromycin and tetracycline resistance in the Faroe Islands and Iceland may be associated with antimicrobial use, sudden changes can occur with the introduction of new resistant clones.
dc.description.sponsorshipFaroese Research Council, BP Amoco, Chevron Texaco, Eik V ısindagrunnurin.en
dc.language.isoenen
dc.publisherWileyen
dc.relation.urlhttp://dx.doi.org/ 10.1111/apm.12513en
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/apm.12513/epdfen
dc.rightsArchived with thanks to APMIS : acta pathologica, microbiologica, et immunologica Scandinavicaen
dc.subjectSmitsjúkdómaren
dc.subjectSýklalyfen
dc.subjectBAC12
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshAsymptomatic Diseasesen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDenmarken
dc.subject.meshDrug Resistance, Bacterialen
dc.subject.meshErythromycinen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshInfanten
dc.subject.meshInfant, Newbornen
dc.subject.meshMaleen
dc.subject.meshMicrobial Sensitivity Testsen
dc.subject.meshMiddle Ageden
dc.subject.meshOropharynxen
dc.subject.meshStreptococcal Infectionsen
dc.subject.meshStreptococcus pyogenesen
dc.subject.meshTetracyclineen
dc.subject.meshTonsillitisen
dc.titleAntibacterial resistance in Streptococcus pyogenes (GAS) from healthy carriers and tonsillitis patients and association with antibacterial sale in the Faroe Islands.en
dc.typeArticleen
dc.contributor.department1Microbiological Department, Faroese Food- and Veterinary Authority, Tórshavn, Faroe Islands. 2Medical Faculty, University of Iceland, Reykjavík, Iceland. 3Department of Internal Medicine & Research Unit of the Medical Department, National Hospital of the Faroe Islands, Queen Alexandrines Teaching Hospital, Tórshavn, Faroe Islands. 4Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. 5University of Southern Denmark, Odense, Denmark. 6Faculty of Science and Technology, University of the Faroe Islands, Tórshavn, Faroe Islands. 7Department of Clinical Microbiology, Landspitali University Hospital, Reykjavík, Iceland.en
dc.identifier.journalAPMIS : acta pathologica, microbiologica, et immunologica Scandinavicaen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractThe aim of this study was to investigate the antibacterial resistance of Streptococcus pyogenes (GAS), and correlate the findings with the sales of erythromycin and tetracycline. General practitioners in the Faroe Islands were recruited to send oropharyngeal swabs. From an ongoing pneumococcal study, nasopharyngeal swabs were sampled from healthy children 0-7 years of age. Erythromycin susceptibility data from Iceland were obtained from the reference laboratory at the Landspitali University Hospital. Susceptibility testing in the Faroe Islands and Iceland was performed according to CLSI methods and criteria. The resistance rate to erythromycin and tetracycline found in patients in the Faroe Islands in 2009/2010 was 6% and 30% respectively. Tetracycline resistance in patients declined significantly from 2009 to 2010 (37-10%, p-value = 0.006 < 0.05) and differed significantly between age groups (p-value = 0.03 < 0.05). In Iceland, there was a peak in erythromycin resistance in 2008 (44%) and a substantial decrease in 2009 (5%). Although the prevalence of erythromycin and tetracycline resistance in the Faroe Islands and Iceland may be associated with antimicrobial use, sudden changes can occur with the introduction of new resistant clones.


This item appears in the following Collection(s)

Show simple item record